

ABSTRACT

Provided are a small interfering ribonucleic acid targeting PD-L1, a pharmaceutically acceptable salt thereof, or a ligand conjugate thereof. Further provided are a pharmaceutical composition containing the small interfering ribonucleic acid, the pharmaceutically acceptable salt thereof, or the ligand conjugate thereof, and a therapeutic use of the small interfering ribonucleic acid, the pharmaceutically acceptable salt thereof, or the ligand conjugate thereof.